The Effect of Coffee Consumption on Balance

April 13, 2026 updated by: ESRA PEHLIVAN, Saglik Bilimleri Universitesi
This study aims to investigate the effects of daily coffee consumption on balance performance in healthy university students. Caffeine is a widely consumed psychoactive substance that may influence neuromuscular control, reaction time, and postural stability. Participants will be categorized based on their habitual caffeine intake levels, and balance performance will be assessed using standardized clinical tests. The results are expected to contribute to the understanding of the relationship between caffeine consumption and balance performance.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Caffeine is one of the most commonly consumed psychoactive substances worldwide, primarily ingested through coffee. It acts as a central nervous system stimulant and has been shown to affect alertness, reaction time, and muscular performance. These effects may also influence postural control and balance mechanisms.Balance is a complex function that depends on the integration of visual, vestibular, and proprioceptive systems. Any factor that affects these systems may alter both static and dynamic balance performance. Therefore, examining the effects of daily caffeine consumption on balance is important for both clinical practice and daily life activities.The aim of this study is to evaluate whether different levels of habitual coffee consumption have a significant effect on balance performance in healthy individuals. Participants will be grouped into low, moderate, and high caffeine consumption categories based on their daily intake.Balance performance will be evaluated using standardized assessment tools, including the Y Balance Test, Tandem Walking Test, Timed Up and Go (TUG) Test, and Single Leg Stance Test. The findings of this study are expected to provide evidence regarding the effects of caffeine on neuromuscular control and postural stability.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
32

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

University students age 18-25 years both male and female participants

Description

Inclusion Criteria:

  • Healthy adult
  • Between 18-25 years of age
  • University students
  • Body Mass Index (BMI) < 25 kg/m²
  • Voluntary participation in the study

Exclusion Criteria:

  • Smoking
  • Presence of any systemic, orthopedic, or cardiopulmonary condition that may prevent participation in exercise tests
  • Diagnosed respiratory, vascular, or cardiovascular disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Low coffee consumption group
0-100 mg caffeine consumers.
Other: Daily coffee consumption (self-reported exposure)
Habitual coffee consumption is recorded using a questionnaire and participants are classified into exposure groups (low, moderate, high); no active intervention is performed.
Moderate coffee consumption group
100-300 mg caffeine consumers.
Other: Daily coffee consumption (self-reported exposure)
Habitual coffee consumption is recorded using a questionnaire and participants are classified into exposure groups (low, moderate, high); no active intervention is performed.
High coffee consumption group
>300 mg caffeine consumers.
Other: Daily coffee consumption (self-reported exposure)
Habitual coffee consumption is recorded using a questionnaire and participants are classified into exposure groups (low, moderate, high); no active intervention is performed.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Single Leg Stance Test
Time Frame: Single assessment at baseline
The Single Leg Stance Test will be used to evaluate static balance. Participants will be asked to stand on one leg for as long as possible without support. The duration will be recorded in seconds.
Single assessment at baseline
Y Balance Test
Time Frame: Single assessment at baseline
The Y Balance Test will be used to evaluate dynamic balance. Participants will reach in anterior, posteromedial, and posterolateral directions while maintaining single-leg stance. Reach distances will be measured in centimeters.ere measured in centimeters.
Single assessment at baseline
Timed Up and Go (TUG) Test
Time Frame: Single assessment at baseline
The Timed Up and Go (TUG) test will be used to assess functional mobility and dynamic balance. Participants will be instructed to stand up from a chair, walk 3 meters, turn around, walk back, and sit down. The total time to complete the task will be recorded in seconds.
Single assessment at baseline
Tandem Walking Test
Time Frame: Single assessment at baseline
The Tandem Walking Test will be used to assess dynamic balance. Participants will be instructed to walk in a heel-to-toe manner along a straight line. Performance will be recorded based on time and/or number of errors.
Single assessment at baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Borg Rating of Perceived Exertion (RPE) Scale
Time Frame: Single assessment at baseline
The Borg Rating of Perceived Exertion (RPE) Scale will be used to assess the participant's perceived level of exertion during testing. Participants will rate their effort on a scale ranging from 6 (no exertion) to 20 (maximal exertion).
Single assessment at baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Saglik Bilimleri Universitesi

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Tugba Ceren Yamak, Saglik Bilimleri Universitesi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 13, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 13, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 13, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Coffee&Balance1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings